Skip to main content

Research Repository

Advanced Search

Moxidectin: an oral treatment for human onchocerciasis

Milton, P; Hamley, JID; Walker, M; Basáñez, MG

Authors

P Milton

JID Hamley

M Walker

MG Basáñez



Abstract

Moxidectin is a milbemycin endectocide recently approved for the treatment of human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic in Africa, Yemen, and the Amazonian focus straddling Venezuela and Brazil. Concerns over whether the predominant treatment strategy (yearly mass drug administration (MDA) of ivermectin) is sufficient to achieve elimination in all endemic foci have refocussed attention upon alternative treatments. Moxidectin’s stronger and longer microfilarial suppression compared to ivermectin in both phase II and III clinical trials indicates its potential as a novel powerful drug for onchocerciasis elimination.

Citation

Milton, P., Hamley, J., Walker, M., & Basáñez, M. (2020). Moxidectin: an oral treatment for human onchocerciasis. Expert Review of Anti-infective Therapy, 1-15. https://doi.org/10.1080/14787210.2020.1792772

Journal Article Type Article
Acceptance Date Jul 3, 2020
Publication Date Jul 26, 2020
Deposit Date Aug 14, 2020
Publicly Available Date Mar 28, 2024
Journal Expert Review of Anti-infective Therapy
Print ISSN 1478-7210
Publisher Taylor and Francis
Peer Reviewed Peer Reviewed
Pages 1-15
DOI https://doi.org/10.1080/14787210.2020.1792772
Public URL https://rvc-repository.worktribe.com/output/1376625
Publisher URL https://doi.org/10.1080/14787210.2020.1792772

Files




Downloadable Citations